Y Yeşilova, et al double-blind, placebo-controlled study, however, found no clinical or immunological effects of probiotics of the Lactobacillus strain in serum IL-4, IL-5, and IFN-γ levels in infants with AD compared with the placebo group after three months of treatment20. Another double-blind, placebo-controlled study of 230 infants with atopic eczema/dermatitis syndrome showed no difference in clinical signs and serum IgE levels for the Lactobacillus GG-administered group and the placebo group21. Other clinical studies did not report any difference in cytokine levels after treatment with probiotics13,22. As a result, our study found probiotics effective in reducing AD patients’ SCORAD index, serum IL-5, IL-6, IFN-γ, and total serum IgE levels but not effective in reducing serum IL-2, IL-4, IL-10, ECP, and TNF-α levels. The impact of probiotics on SCORAD indices is thought to be reduced by modification of immunogenicity of poten- tial allergens. Probiotics are effective in the pathogenesis of AD through their effects such as restoring the mucosal barrier function in the intestines, degrading food antigens, regulating the intestinal microbial composition and acti- vities, and stimulating the production of secretory IgA23. They also block Th2 allergic response by stimulating Th1 response13,23-26. Probiotics regulate local and systemic immunity and thus alleviate the severity of clinical symptoms. REFERENCES 1. Kristal L, Klein PA. Atopic dermatitis in infants and children. An update. Pediatr Clin North Am 2000;47:877-895. 2. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI no- menclature task force. Allergy 2001;56:813-824. 3. Bengmark S, García de Lorenzo A, Culebras JM. Use of pro-, pre- and synbiotics in the ICU--future options. Nutr Hosp 2001;16:239-256. 4. Hill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004;80:516-526. 5. Cosickic A, Skokic F, Colic-Hadzic B, Jahic M. Clinical charac- teristics and estimation severity of the atopic dermatitis in children. Med Arh 2010;64:178-182. 6. Carr WW. Improvements in skin-testing technique. Allergy Asthma Proc 2006;27:100-103. 7. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157: 645-648. 8. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256-1264. 192 Ann Dermatol 9. Servin AL, Coconnier MH. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol 2003;17:741-754. 10. Morita H, He F, Fuse T, Ouwehand AC, Hashimoto H, Hosoda M, et al. Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion. Microbiol Immunol 2002;46:293-297. 11. Maassen CB, van Holten-Neelen C, Balk F, den Bak-Glashouwer MJ, Leer RJ, Laman JD, et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 2000;18:2613-2623. 12. Roessler A, Friedrich U, Vogelsang H, Bauer A, Kaatz M, Hipler UC, et al. The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin Exp Allergy 2008;38:93- 102. 13. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93-103. 14. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005;90:892-897. 15. Van Leent EJM, Bos JD. Atopic dermatitis. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. 2nd ed. Berlin: Springer-Verlag, 2003:54-62. 16. Isolauri E. Probiotics in the prevention and treatment of allergic disease. Pediatr Allergy Immunol 2001;12:56-59. 17. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic dis- ease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-1079. 18. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:1869-1871. 19. Sistek D, Kelly R, Wickens K, Stanley T, Fitzharris P, Crane J. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 2006;36:629-633. 20. Brouwer ML, Wolt-Plompen SA, Dubois AE, van der Heide S, Jansen DF, Hoijer MA, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy 2006;36:899-906. 21. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double- blind placebo-controlled trial. Allergy 2005;60:494-500. 22. Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, et al. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 2005;35: 1557-1564. 23. Ouwehand AC. Antiallergic effects of probiotics. J Nutr 2007;137:794S-797S. 24. Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl JP. Molecular and cellular basis of microflora-host interactions. J Nutr 2007;137:756S-772S.